Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

PROLONGED COMPLETE REMISSION FOLLOWING HIGH DOSE CHEMOTHERAPY OF BURKITTS-LYMPHOMA IN RELAPSE CANCER Appelbaum, F. R., Deisseroth, A. B., GRAW, R. G., Herzig, G. P., Levine, A. S., Magrath, I. T., Pizzo, P. A., POPLACK, D. G., Ziegler, J. L. 1978; 41 (3): 1059-1063

Abstract

Fourteen patients with American Burkitt's lymphoma resistant to conventional chemotherapy were treated with high-dose combination chemotherapy and intensive supportive care. Four patients died shortly after chemotherapy, 3 of an acute carditis. All ten remaining patients demonstrated tumor regression and 3 remain in prolonged complete unmaintained remission 29+, 19+, and 9+ months after treatment. These findings demonstrate that high-dose chemotherapy will benefit some patients with Burkitt's lymphoma unresponsive to conventional chemotherapy, but the medullary and extramedullary toxicity of this treatment strategy remains a formidable obstacle.

View details for Web of Science ID A1978ES84800039

View details for PubMedID 638947